 |
Prospector
Profile
118-01
|
| |
| Competitive Technologies, Inc. |
NAICS |
533110 |
| 777 Commerce Drive, Suite 100
Fairfield, CT 06825 |
Description |
Patent Owner & Lessor |
| (203) 368-6044 |
Employees |
15 |
| http://www.competitivetech.net/ |
Revenue |
(mil) |
4.1700 |
| |
Income |
(mil) |
-8.8900 |
| |
Assets |
(mil) |
9.7100 |
| |
Liability |
(mil) |
2.1100 |
| |
(for the year ended 2007-07-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Competitive Technologies, Inc., had a net loss of $2,559,644 on revenues of $ 210,609 for the first quarter ended October 31, 2007, compared with a net loss of $1,122,162 on revenues of $895,176 for the same period last year. The Company's balance sheet at October 31, 2007, showed an accumulated deficit of $30,874,988 and stockholders' equity of only $4,657,860.
|
| |
|
Intellectual Property:
The Company has a concentration of retained royalties derived from its Homocysteine assay technology. The homocysteine assay is a diagnostic blood test used to determine homocysteine levels and a corresponding deficiency of folate or vitamin B12. The Company is actively marketing its other technologies, and seeking new technologies to mitigate this concentration of revenues and provide a steadier future revenue stream. These technologies include Ethyol™, Gallium arsenide and Sexual dysfunction. The Company also has other technologies in its life sciences portfolio, applied science/electronics portfolio and physical sciences portfolio. [SEC Filing 10KSB 10-29-2007]
|
| |
|
Description:
Competitive Technologies, Inc., provides technology transfer, selling and licensing services to intellectual property owners worldwide.
|
| |
|
Officers:
John B. Nano (Pres., CEO & Interim Chief Financial Officer); Aris D. Despo (EVP-Business Development)
|
| |
|
Auditor:
Mahoney Cohen & Company CPA PC
|
| |
|
Securities:
Common Stock-Symbol CTT; AMEX; 8,169,872 common shares outstanding as of December 13, 2007.
|
| |
| |
| |
| return to main page |
|
|
